Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients

D. P. Tashkin, Stephen Israel Rennard, J. Taylor Hays, D. Lawrence, J. P. Marton, T. C. Lee

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease (COPD) weeks to months after quitting smoking. We examined serial changes in spirometry and Clinical COPD Questionnaire (CCQ) scores (measuring respiratory symptoms and health-related quality of life) in COPD participants by smoking status during a smoking cessation trial. In this randomized, double-blind trial, smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d. or placebo for 12 weeks and followed to Week 52. Primary endpoints of abstinence were previously reported. Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s (FEV 1) and CCQ scores. Change from baseline in post-bronchodilator FEV 1 was significantly improved in continuous abstainers (121.8 mL) vs. continuous smokers (37.9 mL) at Week 12 (P = 0.0069), but not at Weeks 24 or 52. Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers (-1.04) vs. continuous smokers (-0.53; P < 0.0001): this improvement was sustained at Weeks 24 and 52. In a 1-year cessation trial of smokers with COPD, continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV 1 at Week 12 (although the difference narrowed subsequently) and CCQ Total Scores at Week 12, with sustained improvement thereafter. (Trial registry: http://www.clinicaltrials. gov; trial identifier: NCT00285012)

Original languageEnglish (US)
Pages (from-to)1682-1690
Number of pages9
JournalRespiratory Medicine
Volume105
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Smoking Cessation
Chronic Obstructive Pulmonary Disease
Lung
Bronchodilator Agents
Smoking
Varenicline
Spirometry
Registries
Placebos
Quality of Life
Surveys and Questionnaires

Keywords

  • Chronic obstructive pulmonary disease
  • Lung function
  • Quality of life
  • Respiratory symptoms
  • Smoking cessation
  • Varenicline

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Tashkin, D. P., Rennard, S. I., Taylor Hays, J., Lawrence, D., Marton, J. P., & Lee, T. C. (2011). Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine, 105(11), 1682-1690. https://doi.org/10.1016/j.rmed.2011.04.016

Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients. / Tashkin, D. P.; Rennard, Stephen Israel; Taylor Hays, J.; Lawrence, D.; Marton, J. P.; Lee, T. C.

In: Respiratory Medicine, Vol. 105, No. 11, 01.11.2011, p. 1682-1690.

Research output: Contribution to journalArticle

Tashkin, DP, Rennard, SI, Taylor Hays, J, Lawrence, D, Marton, JP & Lee, TC 2011, 'Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients', Respiratory Medicine, vol. 105, no. 11, pp. 1682-1690. https://doi.org/10.1016/j.rmed.2011.04.016
Tashkin, D. P. ; Rennard, Stephen Israel ; Taylor Hays, J. ; Lawrence, D. ; Marton, J. P. ; Lee, T. C. / Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients. In: Respiratory Medicine. 2011 ; Vol. 105, No. 11. pp. 1682-1690.
@article{0d4681a2b438407c911a538b0106f58b,
title = "Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients",
abstract = "There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease (COPD) weeks to months after quitting smoking. We examined serial changes in spirometry and Clinical COPD Questionnaire (CCQ) scores (measuring respiratory symptoms and health-related quality of life) in COPD participants by smoking status during a smoking cessation trial. In this randomized, double-blind trial, smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d. or placebo for 12 weeks and followed to Week 52. Primary endpoints of abstinence were previously reported. Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s (FEV 1) and CCQ scores. Change from baseline in post-bronchodilator FEV 1 was significantly improved in continuous abstainers (121.8 mL) vs. continuous smokers (37.9 mL) at Week 12 (P = 0.0069), but not at Weeks 24 or 52. Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers (-1.04) vs. continuous smokers (-0.53; P < 0.0001): this improvement was sustained at Weeks 24 and 52. In a 1-year cessation trial of smokers with COPD, continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV 1 at Week 12 (although the difference narrowed subsequently) and CCQ Total Scores at Week 12, with sustained improvement thereafter. (Trial registry: http://www.clinicaltrials. gov; trial identifier: NCT00285012)",
keywords = "Chronic obstructive pulmonary disease, Lung function, Quality of life, Respiratory symptoms, Smoking cessation, Varenicline",
author = "Tashkin, {D. P.} and Rennard, {Stephen Israel} and {Taylor Hays}, J. and D. Lawrence and Marton, {J. P.} and Lee, {T. C.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.rmed.2011.04.016",
language = "English (US)",
volume = "105",
pages = "1682--1690",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients

AU - Tashkin, D. P.

AU - Rennard, Stephen Israel

AU - Taylor Hays, J.

AU - Lawrence, D.

AU - Marton, J. P.

AU - Lee, T. C.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease (COPD) weeks to months after quitting smoking. We examined serial changes in spirometry and Clinical COPD Questionnaire (CCQ) scores (measuring respiratory symptoms and health-related quality of life) in COPD participants by smoking status during a smoking cessation trial. In this randomized, double-blind trial, smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d. or placebo for 12 weeks and followed to Week 52. Primary endpoints of abstinence were previously reported. Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s (FEV 1) and CCQ scores. Change from baseline in post-bronchodilator FEV 1 was significantly improved in continuous abstainers (121.8 mL) vs. continuous smokers (37.9 mL) at Week 12 (P = 0.0069), but not at Weeks 24 or 52. Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers (-1.04) vs. continuous smokers (-0.53; P < 0.0001): this improvement was sustained at Weeks 24 and 52. In a 1-year cessation trial of smokers with COPD, continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV 1 at Week 12 (although the difference narrowed subsequently) and CCQ Total Scores at Week 12, with sustained improvement thereafter. (Trial registry: http://www.clinicaltrials. gov; trial identifier: NCT00285012)

AB - There are few data concerning changes in lung function and respiratory symptoms in smokers with chronic obstructive pulmonary disease (COPD) weeks to months after quitting smoking. We examined serial changes in spirometry and Clinical COPD Questionnaire (CCQ) scores (measuring respiratory symptoms and health-related quality of life) in COPD participants by smoking status during a smoking cessation trial. In this randomized, double-blind trial, smokers with mild-to-moderate COPD were treated with varenicline 1 mg b.i.d. or placebo for 12 weeks and followed to Week 52. Primary endpoints of abstinence were previously reported. Secondary endpoints were mean changes from baseline in post-bronchodilator forced expired volume in 1 s (FEV 1) and CCQ scores. Change from baseline in post-bronchodilator FEV 1 was significantly improved in continuous abstainers (121.8 mL) vs. continuous smokers (37.9 mL) at Week 12 (P = 0.0069), but not at Weeks 24 or 52. Mean change from baseline at Week 12 in CCQ Total Score was significantly better in continuous abstainers (-1.04) vs. continuous smokers (-0.53; P < 0.0001): this improvement was sustained at Weeks 24 and 52. In a 1-year cessation trial of smokers with COPD, continuous abstinence compared with continuous smoking significantly improved post-bronchodilator FEV 1 at Week 12 (although the difference narrowed subsequently) and CCQ Total Scores at Week 12, with sustained improvement thereafter. (Trial registry: http://www.clinicaltrials. gov; trial identifier: NCT00285012)

KW - Chronic obstructive pulmonary disease

KW - Lung function

KW - Quality of life

KW - Respiratory symptoms

KW - Smoking cessation

KW - Varenicline

UR - http://www.scopus.com/inward/record.url?scp=80052967109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052967109&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2011.04.016

DO - 10.1016/j.rmed.2011.04.016

M3 - Article

VL - 105

SP - 1682

EP - 1690

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 11

ER -